rosiglitazone has been researched along with Huntington Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Braczko, A; Jablonska, P; Jedrzejewska, A; Krol, O; Mierzejewska, P; Pierzynowska, K; Podlacha, M; Slominska, EM; Smolenski, RT; Tomczyk, M; Wegrzyn, G | 1 |
| Chaudhary, T; Kumar, A; Mishra, J | 1 |
| Chen, SJ; Cheng, YC; Chiang, MC; Huang, RN; Lin, KH; Nicol, CJ; Yen, CH | 1 |
| Bronfman, M; Fuenzalida, K; Jin, YN; Johnson, GVW; Quintanilla, RA | 1 |
| Chang, C; Chang, CP; Chen, CM; Chen, HM; Chen, HW; Chern, Y; Chiang, MC; Hung, CH; Kang, JJ; Lee, MR; Tsai, YS; Wu, YR; Wu, YS | 1 |
| Chern, Y; Chiang, MC; Huang, RN | 1 |
| Hwang, WY; Jin, YN; Jo, C; Johnson, GV | 1 |
| Albertz, J; Duan, W; Guo, Z; Jin, J; Peng, Q; Ross, CA; Rudow, G; Troncoso, JC | 1 |
| Hunt, MJ; Morton, AJ | 1 |
9 other study(ies) available for rosiglitazone and Huntington Disease
| Article | Year |
|---|---|
Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.
Topics: Animals; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; Muscle, Skeletal; Neurodegenerative Diseases; PPAR gamma; Rosiglitazone | 2022 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Huntington Disease; Male; Maze Learning; Motor Activity; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxicity Syndromes; PPAR gamma; Quinolinic Acid; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Valproic Acid | 2014 |
Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Heat Shock Transcription Factors; Heat-Shock Proteins; Huntingtin Protein; Huntington Disease; Mice; Mitochondria; Nerve Tissue Proteins; Neuroblastoma; Neuroprotective Agents; Nuclear Proteins; PPAR gamma; Proteasome Endopeptidase Complex; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors; Ubiquitin; Up-Regulation | 2015 |
Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
Topics: Anilides; Animals; Corpus Striatum; Huntingtin Protein; Huntington Disease; Hypoglycemic Agents; Membrane Potentials; Mice; Mitochondria; Mutation; Nerve Tissue Proteins; Nuclear Proteins; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Thapsigargin; Thiazolidinediones | 2008 |
Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Animals; Brain; Down-Regulation; Energy Metabolism; Gene Expression Regulation; Glucose Transporter Type 4; Humans; Huntington Disease; Liver; Lymphocytes; Mice; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Polymerase Chain Reaction; PPAR gamma; Rosiglitazone; Thiazolidinediones; Trans-Activators; Transcription Factors | 2010 |
PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Energy Metabolism; Huntington Disease; Male; Mice; Mice, Transgenic; Mitochondria; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Trinucleotide Repeat Expansion | 2012 |
Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.
Topics: Anilides; Animals; Blotting, Western; Cell Line; Cells, Cultured; Glucose; Huntington Disease; Hydrogen Peroxide; Membrane Potential, Mitochondrial; Mice; Polymerase Chain Reaction; PPAR gamma; Pyruvic Acid; Rats; Reactive Oxygen Species; Rolipram; Rosiglitazone; Superoxides; Thapsigargin; Thiazolidinediones | 2012 |
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Topics: Adenosine Triphosphate; Anilides; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Line; Disease Models, Animal; Gene Expression Regulation; Glutamates; Humans; Huntingtin Protein; Huntington Disease; Hyperglycemia; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Male; Mice; Mice, Transgenic; Movement Disorders; Nerve Tissue Proteins; Neurons; Neuropeptides; Neuroprotective Agents; Orexins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sirtuins; Thiazolidinediones; Trans-Activators; Transcription Factors; Transfection; Trinucleotide Repeat Expansion | 2013 |
Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
Topics: Administration, Oral; Animals; Behavior, Animal; Diabetes Mellitus; Disease Models, Animal; Exocytosis; Glucose Intolerance; Glyburide; Glycosuria; Huntington Disease; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Neurologic Mutants; Mice, Transgenic; Rosiglitazone; Thiazolidinediones | 2005 |